Buccal fentanyl may be valid option during placement of indwelling central venous access port
the ONA take:
Fentanyl buccal tablet is a valid, practical, and safe method of procedural analgesia for patients with cancer during placement of indwelling central venous access systems, a new study published online ahead of print in the journal Supportive Care in Cancer has shown.
Although local anesthesia is most commonly used to overcome pain related to the procedural placement of fully implantable venous access systems in patients with cancer, it may not eradicate all pain. Therefore, researchers sought to evaluate the effectiveness and safety of fentanyl buccal tablet in reducing procedural pain related to the placement of the port in opioid-naïve patients.
For the study, researchers enrolled 65 inpatients who required an indwelling vascular access port. Patients received a 100-mcg fentanyl buccal tablet 10 minutes before preparation of the operating field.
Results showed that nearly 94% of patients experienced no or little pain during the procedure. Only four patients reported a lot of pain, and no patients reported very severe pain.
In regard to safety, 43.1% experienced drowsiness, 9.2% experienced nausea, and 4.7% experienced vomiting, at the end of the procedure. Four hours after the procedure, the rates of drowsiness, nausea, and vomiting were 12.5%, 10.9%, and 7.8%, respectively.
“It will be necessary to perform further studies, taking into account the need for standard antiemetic premedication to [minimize] the incidence of nausea and vomiting,” the authors conclude.
Fentanyl buccal tablet is a valid, practical, and safe method of procedural analgesia for patients with cancer.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Decipher Genomic Classifier Prognostic for Distant Prostate Metastasis
- GUCS 2017: Adjuvant Trials in Post-radical Prostatectomy Prostate Cancer Feasible
- Annual Screening of High-Risk Smokers Only More Cost-effective Than Current Methods
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Metronomic Chemotherapy: Improved Tumor Blood Supply Leads to Better Treatment
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|